Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa
Executive Summary
FDA officials explain why randomized clinical trials of Ebola products are necessary and the Senate passes Ebola priority review voucher bill. Lilly/AstraZeneca start Alzeimer’s trial, Incyte gains new approval for Jakafi, Sunovion files for new use of Aptiom and AstraZeneca resubmits its once withdrawn lung cancer drug Iressa.
You may also be interested in...
AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises
With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.
Ebola Vaccines: FDA Weighs Alternative Study Designs, Approval Pathways
As incidence of Ebola declines, advisory committee will consider alternatives to randomized controlled trials – an approach FDA had previously argued was inappropriate.
ZMapp Ebola Trial To Start ‘Any Day’ With New FDA/NIH Protocol
Study design involves series of pairwise comparisons of novel interventions against optimized standard of care.